Form 8-K - Current report:
SEC Accession No. 0001628280-24-004188
Filing Date
2024-02-12
Accepted
2024-02-12 16:19:42
Documents
17
Period of Report
2024-02-12
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K gthx-20240212.htm   iXBRL 8-K 26761
2 EX-99.1 pressrelease-208interima.htm EX-99.1 8336
6 pressrelease-208interima001.jpg GRAPHIC 281379
7 pressrelease-208interima002.jpg GRAPHIC 228153
  Complete submission text file 0001628280-24-004188.txt   870606

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gthx-20240212.xsd EX-101.SCH 1922
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gthx-20240212_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gthx-20240212_pre.xml EX-101.PRE 13060
18 EXTRACTED XBRL INSTANCE DOCUMENT gthx-20240212_htm.xml XML 2833
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

EIN.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 24620220
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)